Fig. 3

ROC curves of the CLEIA- and RIA-based CCT. The receiver operating characteristic (ROC) curve representing the discriminatory capacity of captopril challenge test (CCT) for primary aldosteronism (PA) in the novel chemiluminescent enzyme immunoassay (CLEIA) and radioimmunoassay (RIA, the conventional assay). The ROC curves and the areas under its curve (AUC) were evaluated in all the 338 cases in panel A and 316 cases after exclusion of PA patients without laterality identification in (B, C). A ROC curve of CLEIA-based CCT, targeting cases with a positive result of RIA-based CCT. B ROC curves of CLEIA-based and RIA-based CCTs for case detection of unilateral PA with positive RIA-based CCT. C ROC curves of CLEIA-based and RIA-based CCTs for case detection of all unilateral PA. In (B, C), the solid and dashed lines represent CLEIA-based CCT and RIA-based CCT, respectively